Illumina (ILMN) Stock Price, News & Analysis

Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Key Stats

• Today's Range: $93.50 to $98.70
• 50-Day Range: $94.20 to $144.40
• 52-Week Range: $93.50 to $156.66
• Volume: 4.23 million shs
• Average Volume: 2.99 million shs
• Market Capitalization: $14.92 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $159.45
• Consensus Rating: Moderate Buy

Illumina Stock Analysis - MarketRank™

Illumina scored higher than 94% of companies evaluated by MarketBeat, and ranked 43rd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Illumina has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 10 buy ratings, 8 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Illumina has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 14.41%

Earnings Growth

Earnings for Illumina are expected to grow by 14.41% in the coming year, from $4.51 to $5.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Illumina is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Illumina is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Illumina has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Illumina has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.11% of the outstanding shares of Illumina have been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Illumina has recently increased by 9.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Illumina does not currently pay a dividend.

Dividend Growth

Illumina does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.11

Percentage of Shares Shorted

4.11% of the outstanding shares of Illumina have been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Illumina has recently increased by 9.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.81

News Sentiment

Illumina has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 27 news articles for Illumina this week, compared to 14 articles on an average week.

Search Interest

Only 36 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.

MarketBeat Follows

18 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 260% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Illumina insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.17% of the stock of Illumina is held by insiders.

Percentage Held by Institutions

89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ILMN Stock Analysis - Frequently Asked Questions

How have ILMN shares performed this year?

Illumina's stock was trading at $133.63 at the beginning of 2025. Since then, ILMN stock has decreased by 29.5% and is now trading at $94.20.
View the best growth stocks for 2025 here.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Thursday, February, 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by $0.06. Illumina had a negative net margin of 27.95% and a positive trailing twelve-month return on equity of 13.37%.
Read the conference call transcript.

Does Illumina have any subsidiaries?

Illumina subsidiaries include these companies: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others.

Who are Illumina's major shareholders?

Top institutional shareholders of Illumina include Capital World Investors (11.37%), Vanguard Group Inc. (9.97%), Loomis Sayles & Co. L P (2.65%) and WCM Investment Management LLC (2.60%). Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt, Charles Dadswell, Phillip G Febbo and Alexander Aravanis.
View institutional ownership trends.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/06/2025
• Today: 2/22/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ILMN
• CUSIP: 45232710
• CIK: 1110803
• Web: www.illumina.com
• Phone: (858) 202-4500
• Fax: 858-202-4766
• Employees: 9,030
• Year Founded: 1998

Price Target and Rating

• Average Stock Price Target: $159.45
• High Stock Price Target: $247.00
• Low Stock Price Target: $100.00
• Potential Upside/Downside: +69.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.62
• Research Coverage: 21 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 20.89
• P/E Growth: 1.6
• Net Income: $-1,223,000,000.00
• Net Margins: -27.95%
• Pretax Margin: -26.97%
• Return on Equity: 13.37%
• Return on Assets: 5.49%

Debt

• Debt-to-Equity Ratio: 0.63
• Current Ratio: 1.77
• Quick Ratio: 1.42

Sales & Book Value

• Annual Sales: $4.37 billion
• Price / Sales: 3.41
• Cash Flow: $4.55 per share
• Price / Cash Flow: 20.72
• Book Value: $14.98 per share
• Price / Book: 6.29

Miscellaneous

• Outstanding Shares: 158,400,000
• Free Float: 158,131,000
• Market Cap: $14.92 billion
• Optionable: Optionable
• Beta: 1.10